Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10336722 Tetrahydroquinoline compositions as BET bromodomain inhibitors

Patent 10336722 was granted and assigned to FORMA Therapeutics on July, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

FORMA Therapeutics

Current Assignee

FORMA Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Adam C. Talbot0

David S. Millan0

George P. Luke0

Matthew W. Martin0

Shawn E. R. Schiller0

Torsten Herbertz0

Goss S. Kauffman0

Katherine J. Kayser-Bricker0

...

Date of Patent

July 2, 2019

Patent Application Number

15937271

Date Filed

March 27, 2018

Patent Citations Received

0

US Patent 10611750 Tetrahydroquinoline compositions as bet bromodomain inhibitors

0

US Patent 10703764 Benzopiperazine compositions as BET bromodomain inhibitors

US Patent 10793561 1,8-naphthyridinone compounds and uses thereof

0

US Patent 11584756 Heterocyclic compounds as BET inhibitors

0

US Patent 11028058 Heterocyclic compounds as adenosine antagonists

US Patent 11254670 1,8-naphthyridinone compounds and uses thereof

US Patent 11306071 Heterocyclic compounds as adenosine antagonists

...

Patent Primary Examiner

D Margaret M Seaman

Patent abstract

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I:

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10336722 Tetrahydroquinoline compositions as BET bromodomain inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool